Similar to finasteride-treated group, significant reductions in IL-8 and TNF-α levels were also shown in the XLQ-treated groups compared with the BPH group (7.42 ± 0.71 ng/ml and 0.84 ± 0.05 ng/ml in the high-dose group, respectively, P<0.01; 9.32 ± 0.60 ng/ml and 1.08 ± 0.07 ng/ml in the low-dose group, respectively, P<0.01). The gene discussed is CXCL8; the disease is benign prostatic hyperplasia.